Can Berkshire's Share Buyback Policy Boost its Bottom Line?
What About BRK.B's Competitors?
Travelers Companies' TRV solid cash generation has allowed it to return capital to shareholders via share buybacks. Travelers returned more than $1.4 billion of excess capital to shareholders, including $0.9 billion in share repurchases, in the first half of 2025. million. As of June 30, 2025, Travelers had $4.29 billion of capacity remaining under its share repurchase authorization approved by the board.Chubb Limited's CB flexible repurchase approach reflects strong capital discipline, supports valuation and signals management's confidence in Chubb's long-term profitability and financial strength. Chubb presently has a $5 billion buyback program under its authorization.
BRK.B's Price Performance
Shares of BRK.B have gained 5% year to date, outperforming the industry.
Image Source: Zacks Investment Research
BRK.B's Expensive Valuation
BRK.B trades at a price-to-book value ratio of 1.56, above the industry average of 1.52. It carries a Value Score of D.
Image Source: Zacks Investment Research
No Estimate Movement for BRK.B
The Zacks Consensus Estimate for BRK.B's second-quarter and third-quarter 2025 EPS witnessed no movement over the past 30 days. The consensus estimate for full-year 2025 and 2026 EPS also witnessed no movement over the past 30 days.
Image Source: Zacks Investment Research
The consensus estimates for BRK.B's 2025 and 2026 revenues indicate year-over-year increases. While the consensus estimate for BRK.B's 2025 EPS indicates a decline, the same for 2026 suggests an increase. BRK.B stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Travelers Companies, Inc. (TRV) : Free Stock Analysis Report
Chubb Limited (CB) : Free Stock Analysis Report
Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Sabre (SABR) Stock Trades Up, Here Is Why
What Happened? Shares of travel technology company Sabre (NASDAQ:SABR) jumped 3.4% in the morning session after investment firm Bernstein upgraded the travel technology company to 'Outperform' from 'Market Perform', suggesting the market has become too pessimistic on its outlook. The upgrade comes even as Bernstein lowered its price target on the stock to $3.00 from $4.00. The move follows a significant plunge in Sabre's stock, which fell nearly 38% in a single day after a recent disappointing quarterly report that missed profit forecasts. However, Bernstein analysts believe the negative market reaction was overblown, stating the stock is now "oversold" and "too cheap." The firm argues that the market is incorrectly pricing in a structural decline for Sabre's core Global Distribution System (GDS) business. Bernstein sees a path for booking declines to stabilize and noted that the company has no major debt maturities until 2027, providing some financial stability. After the initial pop the shares cooled down to $1.92, up 1.6% from previous close. Is now the time to buy Sabre? Access our full analysis report here, it's free. What Is The Market Telling Us Sabre's shares are extremely volatile and have had 33 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was about 1 month ago when the stock dropped 4.1% on the news that the Trump administration announced intentions to impose a 35% tariff on many goods imported from Canada. This move is far more than a typical trade dispute; it targets the United States' largest and most deeply integrated trading partner. Canada is not merely a neighbor but a critical component of North American supply chains, particularly in sectors like automotive, energy, and critical minerals. This move has sparked concerns about potential retaliatory actions and a wider impact on the North American economy, leading to a risk-off sentiment among investors. The S&P 500, Dow Jones Industrial Average, and Nasdaq all opened lower, pulling back from recent record highs and heading for their first weekly loss in three weeks. Sabre is down 46.4% since the beginning of the year, and at $1.92 per share, it is trading 57.6% below its 52-week high of $4.52 from February 2025. Investors who bought $1,000 worth of Sabre's shares 5 years ago would now be looking at an investment worth $224.50. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Why Viatris (VTRS) Stock Is Up Today
What Happened? Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the first generic version of Venofer® Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. This approval marks a significant milestone, as it's the first generic version of Venofer®, a drug with annual U.S. sales of approximately $515 million. Crucially, the U.S. Food and Drug Administration (FDA) also granted Viatris a Competitive Generic Therapy (CGT) designation for two strengths of the drug. This designation provides Viatris with 180 days of market exclusivity, giving the company a significant first-mover advantage to capture market share for this complex-to-manufacture product. After the initial pop the shares cooled down to $9.93, up 2.3% from previous close. Is now the time to buy Viatris? Access our full analysis report here, it's free. What Is The Market Telling Us Viatris's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 3.8% on the news that its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study. The global healthcare company announced that its Phase 3 trial for an ophthalmic ointment, pimecrolimus 0.3% (MR-139), did not achieve its primary endpoint. The study, which involved 477 patients, was designed to evaluate if the treatment led to the complete resolution of debris on the eyelids after six weeks of use. This outcome was not met, prompting the company to re-evaluate the future of the drug's development program. Viatris' Chief R&D Officer, Philippe Martin, stated that the company was considering its next steps, which could include revising an additional planned Phase 3 study for the therapy. The setback in the trial for this eye condition represents a disappointment for the company's pipeline. Viatris is down 20.1% since the beginning of the year, and at $9.93 per share, it is trading 25.8% below its 52-week high of $13.37 from November 2024. Investors who bought $1,000 worth of Viatris's shares 5 years ago would now be looking at an investment worth $596.45. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Why C3.ai (AI) Stock Is Trading Lower Today
What Happened? Shares of artificial intelligence (AI) software company (NYSE:AI) fell 22.6% in the afternoon session after a combination of disappointing preliminary financial results and a major leadership change. The company announced preliminary revenue for its fiscal first quarter that fell well short of analyst expectations and its own previous guidance (roughly 33% below the midpoint of its prior outlook), with CEO Thomas Siebel calling the results "completely unacceptable." Further adding to the uncertainty, Siebel is stepping down from his role due to health reasons, and the company has begun a search for a successor. This dual blow of weak performance and an unexpected leadership transition has led to multiple analyst downgrades and price target cuts, fueling a strong negative sentiment among investors. The stock's decline is a continuation of a broader struggle for the company, which has faced challenges in its growth and profitability despite the overall excitement surrounding the AI sector. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Access our full analysis report here, it's free. What Is The Market Telling Us shares are extremely volatile and have had 38 moves greater than 5% over the last year. But moves this big are rare even for and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 18 days ago when the stock dropped 10% on the news that the company announced it had started a search for a successor to its founder and CEO, Thomas M. Siebel. The enterprise AI software company stated that the decision followed founder and CEO Thomas M. Siebel's diagnosis with an autoimmune disease in early 2025, which led to what was described as a 'significant visual impairment.' This news introduced uncertainty regarding the company's future leadership, which weighed on investor sentiment. Siebel planned to remain in his role until a successor was appointed, after which he was set to transition to the position of Executive Chairman, focusing on strategy and customer relationships. is down 50.6% since the beginning of the year, and at $17.13 per share, it is trading 60.1% below its 52-week high of $42.94 from December 2024. Investors who bought $1,000 worth of shares at the IPO in December 2020 would now be looking at an investment worth $185.16. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
